首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

市場調查報告書

商品編碼

1410091

2023年至2028年控制釋放給藥市場預測

Controlled Release Drug Delivery Market - Forecasts from 2023 to 2028

出版日期: 2023年12月18日 | 出版商:

Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球控制釋放給藥市場預計在預測期內複合年成長率為 6.93%。

允許活性藥物成分 (API) 長時間受控釋放的控釋藥物給藥稱為藥物遞送。與控制釋放藥物輸送相關的眾多好處和慢性病負擔的增加是控制釋放藥物輸送市場的主要成長動力。此外，人口老化需要受控藥物、有利的政府法規以及各種科學研究的技術開拓也有望加強控制釋放藥物輸送市場。

控制釋放藥物傳遞的多重好處

使用控制釋放藥物遞送系統，可以將治療藥物濃度長時間維持在適當的範圍內。控制釋放可透過維持體內恆定的藥物濃度來改善藥物治療。控制釋放給藥系統透過減少劑量次數來提高病患的依從性。減少用藥頻率通常對患者來說更方便，並且可以改善結果。因此，對以持續方式釋放藥物並消除頻繁給藥的需要的控制釋放製劑的需求日益成長，這有望推動控制釋放藥物遞送市場。

慢性病盛行率增加

控制釋放藥物傳遞提供更好的治療效果、更少的劑量變異性和更高的療效，特別是在慢性疾病。因此，慢性病患者數量的增加有望推動控制釋放給藥市場的發展。世界衛生組織（WHO）估計，2019年全球死亡人數中有71%是由慢性病造成的。這包括糖尿病、癌症、慢性呼吸道疾病和心血管疾病等疾病。心血管疾病（CVD）是一種影響世界大部分地區的主要慢性疾病。根據世界衛生組織估計，2019年全球有1,790萬人死亡，佔總死亡人數的32%。

不斷成長的學名藥市場

控制釋放非專利製劑具有與品牌藥物相當的緩釋特性。為了擴大市場，學名藥製造商正在投資開發知名藥物的控制釋放製劑。學名藥的成本效益和不斷上漲的醫療費用正在推動對學名藥的需求。世界各國政府已引入法律規範以促進學名藥的生產和使用。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）制定了學名藥許可法規，以確保學名藥遵守與學名藥藥相同嚴格的品質、安全性和功效標準。我已經創建了一條路徑。

研發費用增加

各種科學研究以及該領域有利的資助計劃正在推動控制釋放藥物輸送市場的發展。 NIBIB 支持生物醫學影像和生物工程（包括藥物傳輸系統）的研究和開發。 NIBIB 資助旨在開發新型藥物輸送系統、提高治療效果和安全性以及提高患者依從性的措施。此外，全球醫療保健支出的增加正在推動控制釋放給藥市場的成長。例如，世界衛生組織預測，2020年全球衛生支出總額將佔全球GDP的近10%。此外，根據美國研究組織的數據，與 2019 年相比，2020 年美國醫療保健研發支出增加了約 11%。

人口老化

市場擴張的關鍵驅動力之一是全球老年人和兒童人口的增加，部分原因是這些年齡層中不遵守處方藥物時間表的比例很高。例如，根據聯合國報告《2019年世界人口展望》，到2050年，60歲及以上的人口預計將增加一倍以上，達到21億人，佔世界人口的20%以上。在人口老化中，老年人的身體、心理和生物能力正在下降，這影響了藥物的吸收。此外，他們的身體無法忍受令人不快的副作用和過量的劑量。因此，由於患者人數迅速增加和人口老化，控制釋放給藥市場預計將擴大。

北美地區預計將大幅成長

預計在預測期內，北美地區將佔據控制釋放給藥市場的主要佔有率。造成這一比例的因素包括慢性病盛行率高、醫療保健支出增加、政府法規、老年人口不斷成長以及技術進步。例如，根據美國疾病管制與預防中心 (CDC) 的數據，到 2020 年，大約十分之六的美國成年人將患有至少一種慢性病，十分之四的人將患有兩種或兩種以上慢性病。我堅持。此外，美國學名藥產業的擴張也是控制釋放給藥市場的一個主要因素。

主要市場參與者

Adair Pharma Solutions 是一家跨國合約開發和受託製造廠商(CDMO)，專門從事口服劑型（包括控制釋放製劑）的開發和製造。該公司的技術包括多顆粒配方、基質系統、滲透系統和包衣顆粒。這些技術允許控制和增強持續藥物釋放引起的藥物釋放曲線。卡樂康是為製藥和營養補充食品提供尖端解決方案和技術支援的全球領導者。該公司的 Opadry® 薄膜包衣用於改善口服固體製劑（包括控制釋放製劑）的耐久性和外觀。一家總部位於美國的全球製藥公司。是一家總部位於美國的全球製藥公司，生產和銷售各種醫藥產品，包括品牌處方藥和非處方藥。該公司的產品包括Keytruda®（派姆單抗）、Januvia®（sitagliptin）、 Gardasil （人類乳突病毒疫苗）和Proquad®（麻疹和水痘疫苗）。

市場主要發展

2022年3月，FDA核准Corium的ADLARITY（經皮）用於治療輕度、中度和重度老年失智症失智症。 2020 年 1 月，醫療技術公司美敦力 (Medtronic) 開發了用於脊髓刺激的 Intelis 平台。為了治療慢性疼痛，該平台利用控制釋放藥物傳遞。它將電刺激設備與植入式藥物幫浦結合起來，隨著時間的推移提供有針對性的疼痛治療。

Managed release drug administration that allows for a prolonged, controlled release of the active pharmaceutical ingredient (API) is referred to as controlled drug delivery. Numerous benefits associated with controlled drug delivery and the growing burden of chronic diseases are major growth drivers in the controlled-release drug delivery market. Moreover, the ageing population with the requirement for controlled drugs, favourable government regulations, and technological developments owing to various scientific research are also expected to bolster the controlled release drug delivery market.

Multiple Associated Benefits of Controlled Release Drug Delivery

Drug levels intended for therapeutic use are kept within the proper range for a longer length of time using controlled-release drug delivery systems. By guaranteeing a constant drug concentration in the body, this controlled release of medication might enhance drug therapy. Reduced dose frequency provided by controlled-release medication delivery systems enhances patient compliance. Less frequent drug use is typically more convenient for patients, which can improve treatment outcomes. The need for controlled-release formulations that offer continuous medication release and eliminate the requirement for frequent dosing is thus on the rise and thereby contemplated to propel the controlled-release drug delivery market.

Increasing Prevalence of Chronic Disease

Controlled-release drug delivery can lead to better treatment results, fewer medication level variations, and greater efficacy, especially in chronic diseases. Thus, the rising cases of chronic illness are contemplated to boost the controlled-release drug delivery market. The World Health Organisation (WHO) estimates that 71% of deaths worldwide in 2019 were caused by chronic diseases. This covers conditions like diabetes, cancer, chronic respiratory conditions, and cardiovascular illnesses. Cardiovascular disease (CVD) is a major chronic disease contributing significant portions worldwide. The WHO estimates that 17.9 million deaths worldwide in 2019 were caused by CVDs, accounting for 32% of all fatalities.

Growing Generic Drug Market

Generic formulations with controlled release provide prolonged release properties comparable to those of their branded equivalents. To expand the market, generic drug producers are making investments in the creation of controlled-release versions of well-known medications. The cost-effectiveness of generic medications and rising healthcare costs are driving up demand for them. Governments all over the world implemented regulatory frameworks to encourage the creation and utilization of generic medications. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) developed paths for the licensing of generic medications, ensuring that they adhere to the same exacting quality, safety, and efficacy criteria as name-brand medications.

Rising Research and Development Expenditure

Various scientific research studies along with the favourable funding programs in the concerned field are propelling the controlled-release drug delivery market. Research and development in biomedical imaging and bioengineering which covers topics including drug delivery systems, is supported by NIBIB. They provide funding for initiatives aimed at creating novel drug delivery systems, promoting therapeutic efficacy and safety, and raising patient compliance. Additionally, the global rising healthcare expenditure is augmenting the controlled-release drug delivery market growth. For instance, WHO predicted that in 2020, total global healthcare spending accounted for almost 10% of the world's GDP. Moreover, the healthcare R&D expenditure in the USA increased by around 11% in 2020 as compared to 2019 according to the Research America Organization.

Aging Population

One of the key drivers of market expansion is the growing worldwide geriatric and pediatric population, which is partly attributable to these age groups' high rates of non-adherence to prescribed medication schedules. For instance, according to the World Population Prospects 2019 report from the United Nations, the number of persons 60 and older is predicted to more than double by 2050, reaching 2.1 billion, or more than 20% of the world's population. Intake of medications is impacted in geriatric populations due to impaired physical, mental, and biological capabilities. Additionally, their body is unable to withstand the unpleasant side effects and excessive doses of medication. Therefore, the controlled-release drug delivery market is contemplated to bolster due to a sharp increase in the patient population and aging population.

North America is Expected to Grow Significantly

The North American region is projected to hold a significant share of the controlled release drug delivery market during the forecasted period. Various factors attributed to such a share are the higher prevalence of chronic disease, increasing healthcare expenditures, government regulation, growing geriatric population, and technological advancements. For instance, approximately 6 in 10 adult Americans were suffering from at least one chronic disease by 2020, and 4 in 10 were having two or more chronic disorders, according to the Centres for Disease Control and Prevention (CDC). Additionally, the widening generic medicine industry in the USA is another major factor in the controlled-release drug delivery market.

Major Market Players

Adare Pharma Solutions is a multinational contract development and manufacturing organization (CDMO) that specializes in the creation and production of oral dosage forms, including formulations with controlled release. Multiparticulates, matrix systems, osmotic systems, and coated pellets are technologies used by to company. These technologies allow for the controlled and extended drug release profiles that result from sustained drug release.
Colorcon is a world leader in terms of providing cutting-edge solutions and technical support to the pharmaceutical and dietary supplement sectors. The company's Opadry® film coatings are used to improve the durability and appearance of oral solid dosage forms, including controlled-release formulations.
Merck & Co., Inc. is a global pharmaceutical corporation with its corporate headquarters in the United States. Merck manufactures and distributes a wide selection of pharmaceutical goods, including both branded prescription drugs and over-the-counter (OTC) items. Products offered by the company are Keytruda® (pembrolizumab), Januvia® (sitagliptin), Gardasil® (human papillomavirus vaccination), and ProQuad® (measles, and varicella vaccine).

Key Market Developments

In March 2022, the FDA approved Corium's ADLARITY (donepezil transdermal system) as a treatment for those with mild, moderate, or severe Alzheimer's-related dementia, according to Corium, Inc.
In January 2020, the Intellis platform for spinal cord stimulation was developed by the medical technology company Medtronic. To treat chronic pain, this platform makes use of controlled-release drug delivery. It combines an electrical stimulation device with an implanted medication pump to deliver targeted pain treatment over time.

Segmentation:

By Technology

Micro Encapsulation
Transdermal
Targeted delivery
Others

By Release Mechanism

Polymer Based Systems
Micro Reservoir Partition Controlled Drug Delivery Systems
Feedback Regulated Drug Delivery Systems
Activation-modulated Drug Delivery Systems
Chemically Activated

By Application

Metered Dose Inhalers
Injectable
Transdermal and Ocular Patches
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY TECHNOLOGY

5.1. Introduction
5.2. Micro Encapsulation
5.3. Transdermal
5.4. Targeted delivery
5.5. Others

6. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY RELEASE MECHANISM

6.1. Introduction
6.2. Polymer Based Systems
6.3. Micro Reservoir Partition Controlled Drug Delivery Systems
6.4. Feedback Regulated Drug Delivery Systems
6.5. Activation-modulated Drug Delivery Systems
6.6. Chemically Activated

7. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY APPLICATION

7.1. Introduction
7.2. Metered Dose Inhalers
7.3. Injectable
7.4. Transdermal and Ocular Patches
7.5. Others

8. CONTROLLED RELEASE DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others